Acoramidis (356 mg film-coated tablets)
Pre-clinicalRecruiting 0 watching 0 views this week💤 Quiet
20
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Conditions
Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Trial Timeline
Oct 29, 2025 → Jul 3, 2028
NCT ID
NCT07235462About Acoramidis (356 mg film-coated tablets)
Acoramidis (356 mg film-coated tablets) is a pre-clinical stage product being developed by Bayer for Transthyretin Amyloid Cardiomyopathy (ATTR-CM). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07235462. Target conditions include Transthyretin Amyloid Cardiomyopathy (ATTR-CM).
Hype Score Breakdown
Clinical
5
Activity
2
Company
7
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07235462 | Pre-clinical | Recruiting |
Competing Products
20 competing products in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Eplontersen Solution for Injection | AstraZeneca | Phase 1 | 33 |
| Eplontersen + Placebo | AstraZeneca | Phase 3 | 77 |
| Treatment of transthyretin (ATTR) amyloidosis in observational study setting | AstraZeneca | Pre-clinical | 23 |
| Eplontersen | AstraZeneca | Phase 3 | 77 |
| Eplontersen + Placebo | AstraZeneca | Phase 3 | 77 |
| NNC6019-0001 + Placebo (NNC6019-0001) | Novo Nordisk | Phase 3 | 76 |
| NNC6019-0001 | Novo Nordisk | Phase 2 | 51 |
| NNC6019-0001 + Placebo (NNC6019-0001) | Novo Nordisk | Phase 2 | 51 |
| Coramitug | Novo Nordisk | Phase 1 | 32 |
| Tafamidis | Pfizer | Pre-clinical | 22 |
| Tafamidis | Pfizer | Pre-clinical | 22 |
| tafamidis meglumine | Pfizer | Approved | 84 |
| Fx-1006A | Pfizer | Phase 2 | 51 |
| Tafamidis | Pfizer | Phase 3 | 76 |
| Tafamidis 61 milligrams | Pfizer | Pre-clinical | 22 |
| Treatment for TTR amyloidosis + Treatment for TTR amyloidosis | Pfizer | Pre-clinical | 22 |
| Vyndaqel | Pfizer | Pre-clinical | 22 |
| tafamidis | Pfizer | Phase 3 | 76 |
| Tafamidis | Pfizer | Approved | 84 |
| Tafamidis | Pfizer | Pre-clinical | 22 |